| 摘要 |
The invention concerns 6-oxo-9-fluor-prostaglandin derivatives of formula (I) in which R<1> is a COOR<2> or CONHSO2R<2> residue in which R<2> is a C5 to C6 cycloalkyl group or a C6 to C12 aryl group or a 5- or 6-membered heterocyclic residue, or if R<1> is COOR<2>, R<2> is a hydrogen atom or a free phenacyl or a phenacyl substituted with 1 to 3 halogen atoms; A is an E-configured CH=CH- or -C=C-group; W is a free of functionally modified hydroxymethyl group or a free or functionally modified group (a), in which the OH group in each case can be in the alpha or beta position; D is a straight-chain or branched alkylene group with 1 to 5 carbon atoms or a direct bond; E is a -C=C- group, a C2 to C4 alkylene group or a group (b); R<3> is a hydrogen atom, a C1 to C10 alkenyl group, a C3 to C10 cycloalkyl group or a possibly substituted C6 to C12 aryl group or a 5- or 6-membered heterocyclic group; R<4> is a hydrogen atom, a methyl group or a free or functionally modified hydroxy group, and if R<2> is a hydrogen atom, their salts with physiologically compatible bases, the alpha , beta or gamma cyclodextrin clathrates and the liposome-encapsulated compounds of formula (I), a process for producing them and their use as drugs. |
